Form 4: Pfizer Director Acquires Phantom Stock Units

Pfizer Director James Quincey reported the acquisition of 1,556.225 phantom stock units as deferred director's compensation.

Summary

• James Quincey, a Director of Pfizer Inc. (PFE), reported the acquisition of 1,556.225 Phantom Stock Units.
• These units represent deferred director's compensation, including dividend equivalents, and are settled in cash or common stock at the director's election following retirement from the Board of Directors.
• The transaction date for the acquisition was December 31, 2025, with each unit valued at $24.9.
• Following this transaction, James Quincey beneficially owns a total of 74,697.055 derivative securities, specifically Phantom Stock Units.

Sentiment

Score: 6

Explanation: The filing reports a routine, non-open market acquisition of phantom stock units as part of a director's compensation package. This increases the director's beneficial ownership and aligns interests with shareholders, which is generally positive, but it does not represent a direct cash investment or new strategic development.

Positives

• The acquisition of phantom stock units aligns the director's financial interests with those of shareholders, as the value of these units is tied to the company's common stock performance.
• Increased beneficial ownership by a director can signal confidence in the company's long-term prospects.

Negatives

• The transaction represents deferred compensation rather than an open market purchase, meaning there is no direct cash investment by the director at this time.

Future Outlook

The nature of the phantom stock units, which are settled upon the director's retirement, implies a long-term perspective on the company's performance and value.

Industry Context

Insider transactions, particularly those related to executive and director compensation involving equity-based awards, are a standard practice across various industries, including the pharmaceutical sector. Such compensation structures are designed to align the interests of company leadership with those of shareholders.

Comparison to Industry Standards

• Equity-based compensation, such as phantom stock units, is a common practice for director remuneration across various industries, including pharmaceuticals, to align director interests with shareholder value.
• The specific value and number of units are consistent with typical compensation structures for directors of large public companies like Pfizer, though direct comparisons to specific peer companies are not provided in this filing.

Related Party Transactions

• Acquisition of 1,556.225 Phantom Stock Units by Director James Quincey as deferred director's compensation, valued at $24.9 per unit.

Stakeholder Impact

• Shareholders: The equity-based compensation structure for the director helps align their long-term interests with those of the shareholders, potentially fostering decisions that enhance shareholder value.

Key Dates

Recommendation

This Form 4 reports a routine acquisition of phantom stock units as part of director compensation, not an open market purchase. While it increases the director's beneficial ownership and aligns interests, it does not provide new fundamental information to warrant a change in investment recommendation based solely on this filing.

Keywords

Pfizer, PFE, James Quincey, Form 4, Insider Transaction, Phantom Stock Units, Director Compensation, Beneficial Ownership